Objective This post hoc analysis compared anifrolumab 300 mg every 4 weeks with placebo
on rash and arthritis measures with different stringency in patients with moderate to severe …

Background Type I interferons (IFNs) appear to play a central role in disease pathogenesis
in systemic lupus erythematosus (SLE), making them potential therapeutic targets. Methods …

Objective In phase II and III trials, anifrolumab, a human monoclonal antibody that binds type
I interferon receptor subunit 1, has shown efficacy in adults with moderate to severe SLE. We …

Objective Anifrolumab is a fully human immunoglobulin G1 κ monoclonal antibody specific
for subunit 1 of the type I interferon (IFN) α receptor. In a phase IIb study of adults with …

Background Systemic lupus erythematosus (SLE) management objectives include
preventing disease flares while minimizing glucocorticoid exposure. Pooled data from the …

Objective To assess the efficacy and safety of the type I interferon receptor antibody,
anifrolumab, in patients with active, biopsy-proven, Class III/IV lupus nephritis. Methods This …

Anifrolumab (anifrolumab-fnia; Saphnelo™) is a monoclonal antibody antagonist of the type
1 interferon receptor (IFNAR). It is being developed by AstraZeneca (under license from …

Objectives The efficacy and safety of sifalimumab were assessed in a phase IIb,
randomised, double-blind, placebo-controlled study (NCT01283139) of adults with …

Current therapies for systemic lupus erythematosus (SLE), a debilitating, potentially lethal,
multifactorial systemic autoimmune disease, are limited to suppressing disease activity and …

Objectives In a post-hoc analysis, we aimed to validate the Lupus Low Disease Activity State
(LLDAS) definition as an endpoint in an systemic lupus erythematosus (SLE) Phase IIb …